HIV/HCV共感染者外周血辅助性T细胞17和IL-17A水平检测*

doi:10.3969/j.issn.1672-5069.2015.01.008

摘要/Abstract

摘要： 目的探讨HIV/HCV共感染者外周血辅助性T细胞17（Th17）及白细胞介素（IL）-17A的免疫调节作用。方法随机选取HIV/HCV共感染者、HIV感染者、HCV感染者和健康人各30例,使用流式细胞仪检测外周血CD4⁺T细胞数量和Th17数量,采用ELISA法检测血清IL-17A水平。结果 HIV感染者和HIV/HCV共感染者CD4⁺T淋巴细胞分别为（310.23±114.35）个/μl和（218.42±112.47）个/μl,均较健康人明显降低[（735.46±121.52）个/μl,P<0.05],HIV/HCV共感染者较HIV感染者CD4⁺T淋巴细胞更低（P<0.05）,HCV感染者CD4⁺T淋巴细胞数为（719.47±123.72）个/μl,与健康人比较无显著性差异;HIV感染者Th17百分比和IL-17A水平分别为（2.48±0.90）%,和（25.18±12.63）pg/ml,均较健康人显著降低[（3.95±1.23）%和（39.15±16.30）pg/ml,P<0.05],HCV感染者Th17百分比和IL-17A为（5.48±0.90）%和（45.24±15.72）pg/ml,显著高于健康人（P<0.05）,而HIV/HCV共感染者Th17百分比为（1.76±0.42）%,IL-17A为（16.49±7.54）pg/mL,均显著低于HIV感染者[（2.48±0.90）%和（25.18±12.63）pg/mL,P<0.05]。结论合并HCV感染可能通过影响Th17及其细胞因子IL-17A进一步影响HIV患者的免疫功能。

关键词: 丙型肝炎, 艾滋病, T淋巴细胞, 辅助性T细胞17, 白细胞介素17A

Abstract: Objective To explore the changes in Thl7 cell counts and serum IL-17A levels in HIV/HCV co-infected patients. Methods Thirty HIV/HCV co-infected patients,30 HIV infected patients,30 HCV infected patients and 30 healthy subjects were selected in this study. The percentage of CD4⁺T cells and Th17 cells in peripheral blood,and IL-17A in sera were detected by FCM and ELISA,respectively. Results The percentage of CD4⁺T cells in HIV and HIV/HCV co-infected patients were （310.23±114.35）/μl and（218.42±112.47）/μl,respectively,both were significantly lower than that in the healthy controls[（735.46±121.52）/μl,P<0.05],while the percentage of CD4⁺T cells in HIV/HCV co-infected group was even lower than in HIV infected patients（P<0.05）; There was no significant difference in CD4⁺T cells between HCV infected patients[（719.47±123.72）/μl] and the controls;The percentage of Th17 and serum level of IL-17A in HIV infected patients were（2.48±0.90）% and （25.18±12.63）pg/ml,significantly lower than those in the controls [（3.95±1.23）% and（39.15±16.30）pg/ml,P<0.05];The percentage of Th17 and serum level of IL-17A in HCV infected patients were（5.48±0.90）% and（45.24±15.72）pg/ml,significantly higher than those in the controls（P<0.05）;The percentage of Th17 and serum level of IL-17A in HIV/HCV co-infected patients were（1.76±0.42）% and（16.49±7.54） pg/ml,both significantly lower than those in HIV infected patients[（2.48±0.90）% and （25.18±12.63）pg/mL,P<0.05]. Conclusions Co-infection of HCV may influence the immune response in HIV infected patients,which might lead to the involvement of Th17 and IL-17A cytokine.

Key words: Hepatitis C, Human immunodeficiency virus, T lymphocytes, T helper cell 17, Interleukin 17A

丁佩佩, 何纲, 陈晓华, 甄沛林, 吴兴柳, 胡长征. HIV/HCV共感染者外周血辅助性T细胞17和IL-17A水平检测^*[J]. 实用肝脏病杂志, 2015, 18(1): 30-33.

Ding Peipei, He Gang, Chen Xiaohua, et al.. Th17 cell counts in peripheral blood and serum IL-17A levels in HIV/HCV co-infected patients[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 30-33.

参考文献

[1] Zhou YH,Liu FL,Yao ZH,et a1. Comparison of HIV-,HBV-,HCV-and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region. PloS One,2011,6（1）：e16349.
[2] Chen X,He JM,Ding LS,et a1. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. Arch Virol,2013,158（9）：1889-1894.
[3] Ladep NG,Agaba PA,Agbaji O,et al. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol,2013,19（10）:1602-1610.
[4] Raboud J,Anema A,Su D,et a1. Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy. HIV Clin Trials,2012,13（2）：90-102.
[5] Dimitroulis D,Spartalis E,Pikoulis E,et al. Hepatocellular carcinoma in patients co-infected with hepatitis C virus and human immunodeficiency virus. World J Hepatol,2013,5（6）:323-327.
[6] 中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南（2011版）. 中华传染病杂志,2011,29（10）：629-640.
[7] 中华医学会肝病学分会和传染病与寄生虫病学分会.丙型肝炎防治指南. 中华肝脏病杂志,2004,12（4）:194-198.
[8] Lambotin M,Barth H,Moog C,et al. Challenges for HCV vaccine development in HIV-HCV co-infection. Expert Rev Vaccines,2012,11（7）:791-804.
[9] Deng LP,Gui XE,Zhang YX,et al. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection：a meta-analysis. World J Gastroenterol,2009,15（8）:996-1003.
[10] Rauch A,Gaudieri S,Evison J,et al. Low current and nadir CD4 + T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antivir Ther,2008,13（3）:455-460.
[11] 何纲,谭雁冰,刘翠珍,等.HCV对中国HIV/HCV共感染者白细胞介素-7/白细胞介素-7受体的影响.实用医学杂志,2014,30（1）:64-66.
[12] Sajadi MM, Redfield RR, Talwani R. Altered T-cell subsets in HIV-1 natural viral suppressors（elite controllers） with hepatitis C infection. AIDS,2013,27（12）:1989-1992.
[13] Reiberger T,Ferlitsch A,Sieghart W,et al. HIV-HCV co-infected patients with low CD4 + cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat,2010,17（6）:400-409.
[14] Park H,Li Z,Yang XO,et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol,2005,6（11）:1133-1141.
[15] Sierro S,Romero P,Speiser DE.The CD4-like molecule LAG-3,biology and therapeutic applications.Expert Opin Ther Targets,201l,15（1）：91-101.
[16] Zrioual S,Ecochard R,Toumadre A,et a1.Genome-wide comparison between IL-17A-and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol,2009,182（5）：3112-3120.
[17] Kumar A,Hilja K,Curt S,et al. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol Immunol,2013,5（3-4）: 355-364.
[18] Kisand K,Wolff B,AS Podkrajsek K. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Experiment Med,2010,207（2）:299-308.
[19] Prendergast A,Prado JG,Kang YH,et a1. HIV-l infection is characterized by profound depletion of CDl61+Th17 cells and gradual decline in regulatory T cells.AIDS,2010,24（4）：491-502.
[20] Lee HC,Sung SS,Krueger PD,et a1. Hepatitis C virus promotes T-helper（Th）17 responses through thymic stromal lymphopoietin production by infected hepatocytes. Hepatology,2013,57（4）:1314-24.

HIV/HCV共感染者外周血辅助性T细胞17和IL-17A水平检测^*

Th17 cell counts in peripheral blood and serum IL-17A levels in HIV/HCV co-infected patients

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[2]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[3]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[4]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[5]	刘立, 李俊义, 杜映荣, 刘春云, 李卫昆, 王辉, 李惠敏, 常丽仙, 祁燕伟. 索磷布韦/达拉他韦治疗慢性丙型肝炎患者疗效及安全性分析：一项真实世界研究[J]. 实用肝脏病杂志, 2019, 22(3): 361-364.
[6]	周积云,马勇,丁体龙,涂远航,陈策. 慢性乙型肝炎患者外周血CD8⁺CD28⁺T淋巴细胞百分比的变化及其临床意义探讨[J]. 实用肝脏病杂志, 2019, 22(2): 180-183.
[7]	蒋奕,刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析[J]. 实用肝脏病杂志, 2019, 22(2): 188-191.
[8]	吴静,东保吉,吴超. 慢性丙型肝炎患者外周血滤泡辅助性T淋巴细胞表面PD-1受体表达及意义研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 192-195.
[9]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[10]	杨珍杰,李洪涛,王剑,李霞,陈媛. 聚乙二醇化干扰素α-2a联合利巴韦林治疗代偿期丙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 232-235.
[11]	侯春阳, 马玉梅, 李方治. Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 53-56.
[12]	王禅, 秦伟, 戴勇, 李晓峰, 张成强. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者临床疗效及其对外周血T淋巴细胞亚群的影响[J]. 实用肝脏病杂志, 2019, 22(1): 97-100.
[13]	徐溪, 党引利, 吴朔. HCV感染相关干扰素L4真核表达载体的构建与表达[J]. 实用肝脏病杂志, 2018, 21(6): 833-836.
[14]	刘映川, 赵鹏程, 游亭, 邓红英, 薛江凤. 熊去氧胆酸联合维生素D治疗PBC患者疗效和外周血T淋巴细胞亚群的变化[J]. 实用肝脏病杂志, 2018, 21(6): 907-910.
[15]	周思思, 沈有秀, 李娟, 俞科贤. 慢性丙型肝炎和肝硬化患者外周血Th17和Treg细胞及其相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2018, 21(5): 689-692.